FDA to introduce Wholesale Distributor Verification Requirements

Recommendation
9 September 2025
Basel, Switzerland
Specifics in the Distribution of Medicinal Products
The US Food and Drug Administration FDA has published a Compliance Policy Guidance for Industry "Wholesale Distributor Verification Requirement for Saleable Returned Drug Product".
This Guidance is part of FDA's Drug Supply Chain Security Act (DSCSA) and will require wholesale distributors to verify a product identifier prior to further distributing returned product. To address concerns expressed by stakeholders and to minimize possible disruptions in the pharmaceutical distribution supply chain, FDA does not intend to take action against wholesale distributors who do not, prior to November 27, 2020, verify a product identifier prior to further distributing returned product as required under the DSCSA. This represents a 1-year delay in enforcement of this DSCSA requirement.
Related GMP News
10.06.2025Stimuli Article Proposes Revision of USP Definition of Controlled Room Temperature (CRT)
10.06.2025New MHRA Blog Post: Supplying Medicines to Ships, Aircraft and Oil Platforms
10.06.2025Questions and Answers from the ECA Webinar "GDP Update 2025" - Part 3
10.06.2025Meet the GDPA Board Members at the GDP Forum in Barcelona
10.06.2025Swissmedic Technical Interpretation: What Counts as a Major Change in GDP?
10.06.2025MHRA informes about Validity Date of UK issued GDP Certificates